Race Oncology Ltd (RAC) - Total Assets
Based on the latest financial reports, Race Oncology Ltd (RAC) holds total assets worth AU$24.77 Million AUD (≈ $17.52 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Race Oncology Ltd (RAC) net assets for net asset value and shareholders' equity analysis.
Race Oncology Ltd - Total Assets Trend (2011–2025)
This chart illustrates how Race Oncology Ltd's total assets have evolved over time, based on quarterly financial data.
Race Oncology Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Race Oncology Ltd's total assets of AU$24.77 Million consist of 85.5% current assets and 14.5% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 78.1% |
| Accounts Receivable | AU$29.82K | 0.2% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$2.53 Million | 14.5% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Race Oncology Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Race Oncology Ltd (RAC) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Race Oncology Ltd's current assets represent 85.5% of total assets in 2025, an increase from 46.2% in 2011.
- Cash Position: Cash and equivalents constituted 78.1% of total assets in 2025, up from 2.7% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, a decrease from 18.0% in 2011.
- Asset Diversification: The largest asset category is intangible assets at 14.5% of total assets.
Race Oncology Ltd Competitors by Total Assets
Key competitors of Race Oncology Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $1.30 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥38.02 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.48 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Race Oncology Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 18.37 | 20.59 | 50.35 |
| Quick Ratio | 18.37 | 20.59 | 50.35 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$20.07 Million | AU$18.08 Million | AU$5.64 Million |
Race Oncology Ltd - Advanced Valuation Insights
This section examines the relationship between Race Oncology Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 20.30 |
| Latest Market Cap to Assets Ratio | 19.24 |
| Asset Growth Rate (YoY) | -13.5% |
| Total Assets | AU$17.49 Million |
| Market Capitalization | $336.55 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Race Oncology Ltd's assets at a significant premium (19.24x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Race Oncology Ltd's assets decreased by 13.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Race Oncology Ltd (2011–2025)
The table below shows the annual total assets of Race Oncology Ltd from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$17.49 Million ≈ $12.38 Million |
-13.54% |
| 2024-06-30 | AU$20.23 Million ≈ $14.31 Million |
-24.06% |
| 2023-06-30 | AU$26.64 Million ≈ $18.85 Million |
-29.01% |
| 2022-06-30 | AU$37.52 Million ≈ $26.55 Million |
+163.41% |
| 2021-06-30 | AU$14.25 Million ≈ $10.08 Million |
+140.08% |
| 2020-06-30 | AU$5.93 Million ≈ $4.20 Million |
+13.19% |
| 2019-06-30 | AU$5.24 Million ≈ $3.71 Million |
-36.39% |
| 2018-06-30 | AU$8.24 Million ≈ $5.83 Million |
+37.32% |
| 2017-06-30 | AU$6.00 Million ≈ $4.25 Million |
+34.26% |
| 2016-06-30 | AU$4.47 Million ≈ $3.16 Million |
+3490.93% |
| 2015-06-30 | AU$124.47K ≈ $88.07K |
+101.40% |
| 2014-06-30 | AU$61.80K ≈ $43.73K |
-99.98% |
| 2013-12-31 | AU$289.97 Million ≈ $205.18 Million |
+275467.34% |
| 2013-06-30 | AU$105.23K ≈ $74.46K |
-99.97% |
| 2012-12-31 | AU$360.83 Million ≈ $255.31 Million |
-15.29% |
| 2012-06-30 | AU$425.96 Million ≈ $301.39 Million |
+12.02% |
| 2011-06-30 | AU$380.25 Million ≈ $269.05 Million |
-- |
About Race Oncology Ltd
Racura Oncology Ltd operates as a Phase 3 clinical biopharmaceutical company for cancer care. Its lead asset is RCDS1 (E,E-bisantrene), a small molecule anticancer agent that primarily functions through G4-DNA & RNA binding to potent inhibition of the cancer growth regulator MYC. The company is advancing a proprietary formulation of RCDS1 (RC220) to address the unmet needs of patients across vari… Read more